DataString Consulting Company Logo
DataString Consulting Company Logo
Avapritinib Market
Home»Recent Reports»Avapritinib Market

Avapritinib Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802158, Published - March 2025

Segmented in Application (Gastrointestinal Stromal Tumors, Systemic Mastocytosis, Other Rare Cancers), Patient Demographic (Pediatric, Adult, Geriatric), Therapy Combination, Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Avapritinib Market Outlook

The market, for Avapritinib was estimated at $516.0 million in 2024; and it is anticipated to increase to $832.6 million by 2030 with projections indicating a growth to around $1.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.3% over the forecast period. The importance of avapritinib in the market cannot be overstated as it caters to the increasing cases of stromal tumors (GIST) and systemic mastocytosis – the primary areas where avapritinib is applied for therapy purposes. Avapritinibs strong TKI effects and the support from research endeavors and favorable regulatory perspectives are driving its market relevance upwards. Moreover the growing acceptance of medicine further cements avapritinibs position, in the marketplace. The pharmaceutical industry is increasingly embracing avapritinib as treatment approaches move towards personalized therapies tailored to individual patients.


Avapritinib is a game changer in treating GIST and systemic mastocytosis by acting as a protein kinase inhibitor that focuses on the PDGFRA D842V mutation in GIST patients. The developments in gene therapy and technology have further boosted its importance, in the field.


Market Size Forecast & Key Insights

2019
$516M2024
2029
$1.1B2034

Absolute Growth Opportunity = $629M

The Avapritinib market is projected to grow from $516.0 million in 2024 to $1.15 billion in 2034. This represents a CAGR of 8.3%, reflecting rising demand across Oncological Treatment, Systemic Mastocytosis Treatment and Gastrointestinal Stromal Tumors Treatment.

The Avapritinib market is set to add $629 million between 2024 and 2034, with manufacturer targeting Adult & Geriatric Patient Demographic projected to gain a larger market share.

With Rise in gastrointestinal stromal tumors , and Intensified research and development activities, Avapritinib market to expand 122% between 2024 and 2034.

Opportunities in the Avapritinib Market

Strategic Collaborations for Expanding Market access

In the pharmaceutical sector forming strategic alliances is essential for accelerating advancements and offering holistic solutions which benefit both Avapritinib and patients globally to expand its market presence effectively through collaborations with major players, in the industry.

Precision Medicine Evolution and Untapped Potential in Emerging Markets

Precision Medicine offers an opportunity for avapritinibs advancement as a next generation treatment option with the potential to be even more effective when integrated with the evolving realm of personalized medicine. By focusing on characteristics and how individuals respond to treatment uniquely tailored to them in this area of healthcare advancement can customize avapritinib to meet specific patient requirements and optimize its effectiveness, in treating cancer.

Taking into account the changing demands of individuals with cancer in developing regions and the increasing focus on patient centered healthcare approaches along with rising investments in healthcare, in those regions; avapritinib shows growth potential by targeting new patient groups and broadening its market presence.

Growth Opportunities in North America and Europe

Europe Outlook

The Avapritinib market in Europe stands out as a region with high demand coming from countries like the United Kingdom, Germany and France. The increasing focus on personalized healthcare and precision oncology in Europe has expanded the usage of avapritinib. However it faces competition from next. Generation tyrosine kinase inhibitors in the market. The growing demand for avapritinib is fueled by an aging populationthat'smore prone to variouss of cancer requiring treatments, like avapritinib. Moreover partnerships, between pharmaceutical companies and research organizations stimulate market expansion by accelerating the approval of new drugs.

North America Outlook

In North America's field. Avapritinib shows promise due to a healthcare system and active pharmaceutical research scene. The United States in particular is embracing cancer therapies like Avapritinib. In spite of this potential. Avapritinib faces competition from other targeted treatments such as Dasatinib and Imatinib. Growth in stromal tumors and systemic mastocytosis is a key factor driving demand, for avapritinib. The need, for this is boosted by clinical trials and research and development efforts focusing on new uses of avapritinib.

North America Outlook

In North America's field. Avapritinib shows promise due to a healthcare system and active pharmaceutical research scene. The United States in particular is embracing cancer therapies like Avapritinib. In spite of this potential. Avapritinib faces competition from other targeted treatments such as Dasatinib and Imatinib. Growth in stromal tumors and systemic mastocytosis is a key factor driving demand, for avapritinib. The need, for this is boosted by clinical trials and research and development efforts focusing on new uses of avapritinib.

Europe Outlook

The Avapritinib market in Europe stands out as a region with high demand coming from countries like the United Kingdom, Germany and France. The increasing focus on personalized healthcare and precision oncology in Europe has expanded the usage of avapritinib. However it faces competition from next. Generation tyrosine kinase inhibitors in the market. The growing demand for avapritinib is fueled by an aging populationthat'smore prone to variouss of cancer requiring treatments, like avapritinib. Moreover partnerships, between pharmaceutical companies and research organizations stimulate market expansion by accelerating the approval of new drugs.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, United Kingdom, Germany, Japan, China are expected to grow at 6.1% to 8.7% CAGR

2

Emerging Markets : Brazil, Turkey, South Africa are expected to grow at 8.0% to 10.4% CAGR

Market Analysis Chart

The worldwide market trends for Avapritinib in the field of oncology are greatly impacted by factors that drive or limit its growth potential significantly. One key element propelling its market expansion is the rising occurrence of stromal tumors and systemic mastocytosis. Medical issues that Avapritinib specifically addresses. This increasing prevalence not only boosts the demand for Avapritinib but also spurs investments, in research and development for this therapeutic solution.

Recent Developments and Technological Advancement

December 2024

Pfizer Inc., a pharmaceutical company has revealed a partnership with Blueprint Medicines Corporation to further their exploration of avapritinib, in combating gastrointestinal Stromal tumors .

October 2024

Blueprint Medicines Corporation announced results from the Phase III trials of avapritinib for systemic mastocytosis treatment. This development signifies an advancement, in the field of drug research.

June 2024

Roche Laboratories introduced a of avapritinib that aims to reach more patients and shows promising opportunities for growth, in the avapritinib market.

Avapritinib has been gaining attention in the pharmaceutical industry for its role as a groundbreaking kinase inhibitor used in treating stromal tumor and systemic mastocytosis worldwide. Envisioningshapingthe future path of market trends for avapritinibrequires keeping of ongoing advancements and changes, in this field.

Impact of Industry Transitions on the Avapritinib Market

As a core segment of the Pharmaceutical industry, the Avapritinib market develops in line with broader industry shifts. Over recent years, transitions such as Revolutionizing Gastrointestinal Stromal Tumor Treatments and Advancements in Precision Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Avapritinib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Revolutionizing Gastrointestinal Stromal Tumor Treatments:

The introduction of avapritinib marked a change in the field of pharmaceuticals and had a significant impact on oncology practices with a specific focus on gastrointestinal stromal tumors . The advancements surrounding avapritinib have played a role in advancing treatment options for GIST by targeting the PDGFRA gene mutation effectively and providing a potential treatment avenue, for patients affected by this specific genetic alteration. Avapritinibs introduction into the market has brought about a shift in the treatment of GIST patients by offering a better alternative to previous less effective treatments and contributing to the overall growth of the market, in a positive manner.

2

Advancements in Precision Medicine:

Avapritinib has shown to be a driver in accelerating the shift, towards personalized medicine.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Avapritinib market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rise in Gastrointestinal Stromal Tumors , and Expanding Geriatric Population

The rise in the number of patients with stromal tumors has also led to a higher need for avapritinib treatment options. Avapritinib was also given approval by the Food and Drug Administration for targeting and blocking PDGFRA mutations in fourth line GIST cases. This approval has also solidified avapritinib as the choice, among doctors and individuals battling GIST.
The increasing number of individuals is also a significant factor in the rising occurrence of different forms of cancer worldwide. This change in demographics combined with shifts in lifestyle has also resulted in an increase, in the global population of cancer patients.
The ongoing increase in research and development efforts in the sector plays a significant role in driving the demand for avapritinib forward. As medical institutions increasingly recognize the benefits of targeted therapies such as avapritinib there is also a growing emphasis on conducting studies and applying it to various cancer related conditions. Advancements in testing have also made it easier to detect PDGFRA mutations, which has also contributed to the broader adoption of avapritinib, in real world medical settings.

Restraint: Regulatory Constraints

The pharmaceutical industry sees promise in avapritinib and its increasing role in targeted therapies; however meeting strict regulatory standards can be a major obstacle. Industry participants encounter difficulties in adherin to safety regulations and obtaining regulatory nods, which hinders the speed of drug research and market expansion. For example tedious procedures for conducting trials and gaining approvals, for avapritinib can potentially dampen demand and affect market trends accordingly.

Challenge: High Treatment Costs

While avapritinib has demonstrated potential in treating systemic mastocytosis and gastrointestinal stromal tumors effectively​ ​big words​ big words​​​​​​​big words​ big words​​​ ​​big words​ big words​​​​big words​​big words​​ ​​of ​​ ​more ​​of ​more ​of ​​ more of the complex issue about the pricing of pharmaceutical products is influenced by a variety of factors such as research and development costs and the necessity for a profitable return on investment, in the market.

Supply Chain Landscape

API Production

Janssen Pharmaceutica

Sigma-Aldrich

Drug Formulation

Blueprint Medicines

Therachem Research Medilab

Regulatory Compliance
Eurofins Scientific / SGS SA
Sales & Distribution
Johnson & Johnson / McKesson Corporation
API Production

Janssen Pharmaceutica

Sigma-Aldrich

Drug Formulation

Blueprint Medicines

Therachem Research Medilab

Regulatory Compliance

Eurofins Scientific

SGS SA

Sales & Distribution

Johnson & Johnson

McKesson Corporation

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Gastrointestinal Stromal Tumor Treatment
Healthcare
Blueprint Medicines
Placing avapritinib as a market leader through clinical trial success and strategic marketing approaches
Advanced Systemic Mastocytosis Therapy
Healthcare
Blueprint Medicines
Emphasizing unique efficacy of avapritinib via comprehensive clinical trial data publication
R&D in Other Rare Oncology Indications
Research and Development
Blueprint Medicines
Continuous investment in extended clinical trials to broaden avapritinib application spectrum

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Avapritinib market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Avapritinib in Systemic Mastocytosis Treatment, Gastrointestinal Stromal Tumors Treatment and Oncological Treatment

Systemic Mastocytosis Treatment

Avapritinibs significant contribution to treating mastocytosis is remarkable as well. Its ability to block the D816V KIT enzyme has been recognized, making it a viable treatment choice for severe cases of systemic mastocytosis. The key benefit of avapritinib is its capacity to relieve symptoms and enhance the outlook for patients with this condition. This underlines Blueprint Medicines Corporations impact, in this field.

Gastrointestinal Stromal Tumors Treatment

Avapritinib is widely utilized in addressing GIST. has brought about a significant change in treatment approaches in the medical field. One of its strengths lies in its ability to help individuals with advanced stages of GIST who did not only respond to previous treatment methods. The introduction of Avapritinib by Blueprint Medicines Corporation has bolstered their market presence significantly due, to this groundbreaking treatment solution.

Oncological Treatment

Avapritinib is a protein tyrosine kinase inhibitor that is commonly used in cancer treatment. It is particularly effective in targeting mutated enzymes like KIT and PDGFRA. Is preferred for treating uncommons of cancer such as gastrointestinal stromal tumors . Blueprint Medicines Corporation is a player in the industry that has made a name for itself by utilizing this treatment method effectively and establishing a strong presence, in the sector.

Avapritinib vs. Substitutes:
Performance and Positioning Analysis

Avapritinib, contrary to its alternatives such as imatinib and sunitinib, specifically targets PDGFR mutations, potentially positioning it for superior operational effectiveness in treating gastrointestinal stromal tumors. These Alternatives specially Pexidartinib Hydrochloride has experienced a rapid growth as detailed in our latest report.

Avapritinib
  • Imatinib /
  • Sunitinib /
  • Pexidartinib Hydrochloride
    Effective against gastrointestinal stromal tumors, specific mutation targeting capabilities
    Limited scope of application, Potential side effects
    Effective in tumour shrinkage, diversity in treatment applications
    High costs of medication, potential severe side-effects

Avapritinib vs. Substitutes:
Performance and Positioning Analysis

Avapritinib

  • Effective against gastrointestinal stromal tumors, specific mutation targeting capabilities
  • Limited scope of application, Potential side effects

Imatinib / Sunitinib / Pexidartinib Hydrochloride

  • Effective in tumour shrinkage, diversity in treatment applications
  • High costs of medication, potential severe side-effects

Avapritinib, contrary to its alternatives such as imatinib and sunitinib, specifically targets PDGFR mutations, potentially positioning it for superior operational effectiveness in treating gastrointestinal stromal tumors. These Alternatives specially Pexidartinib Hydrochloride has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Avapritinib market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Avapritinib across Gastrointestinal Stromal Tumors, Systemic Mastocytosis, and Other Rare Cancers Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Blueprint Medicines Corporation, Pfizer Inc, and Novartis AG by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including API Production, Drug Formulation, and Regulatory Compliance. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Avapritinib segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning API Production (Janssen Pharmaceutica, Sigma-Aldrich), Drug Formulation (Blueprint Medicines, Therachem Research Medilab), and Regulatory Compliance. Our parallel substitute analysis examines Imatinib, Sunitinib, and Pexidartinib Hydrochloride, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Blueprint Medicines Corporation, Pfizer Inc, and Novartis AG, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Avapritinib market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Avapritinib Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 558 million
Revenue Forecast in 2034USD 1.15 billion
Growth RateCAGR of 8.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024516 million
Growth OpportunityUSD 629 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024516 million USD
Market Size 2027655 million USD
Market Size 2029768 million USD
Market Size 2030832 million USD
Market Size 20341.15 billion USD
Market Size 20351.24 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredApplication, Patient Demographic, Therapy Combination, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBlueprint Medicines Corporation, Pfizer Inc, Novartis AG, AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., Roche Holding AG, Bayer AG, Johnson & Johnson, Merck & Co. Inc and Bristol-Myers Squibb Company
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Avapritinib Market Size, Opportunities & Strategic Insights, by Application

4.1Gastrointestinal Stromal Tumors
4.2Systemic Mastocytosis
4.3Other Rare Cancers
Chapter 5

Avapritinib Market Size, Opportunities & Strategic Insights, by Patient Demographic

5.1Pediatric
5.2Adult
5.3Geriatric
Chapter 6

Avapritinib Market Size, Opportunities & Strategic Insights, by Therapy Combination

6.1Monotherapy
6.2Combination Therapy
Chapter 7

Avapritinib Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Hospital Pharmacies
7.2Retail Pharmacies
7.3Online Pharmacies
Chapter 8

Avapritinib Market, by Region

8.1North America Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Avapritinib Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Blueprint Medicines Corporation
9.2.2Pfizer Inc
9.2.3Novartis AG
9.2.4AstraZeneca plc
9.2.5Eli Lilly and Company
9.2.6GlaxoSmithKline plc
9.2.7Sanofi S.A.
9.2.8Roche Holding AG
9.2.9Bayer AG
9.2.10Johnson & Johnson
9.2.11Merck & Co. Inc
9.2.12Bristol-Myers Squibb Company